Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes - Archive ouverte HAL Access content directly
Journal Articles Nature Communications Year : 2018

Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes

, , , , , (1) , , , , , , , , , , (2) , , , , , (3) , (2) , ,
1
2
3
Amparo Garcia-Lopez
  • Function : Author
  • PersonId : 1046418
Francesca Tessaro
  • Function : Author
Hendrik R A Jonker
  • Function : Author
Anna Wacker
  • Function : Author
Christian Richter
  • Function : Author
Nikolaos Berntenis
  • Function : Author
Roland Schmucki
  • Function : Author
Klas Hatje
  • Function : Author
Olivier Petermann
  • Function : Author
Gianpaolo Chiriano
  • Function : Author
Remo Perozzo
  • Function : Author
Daniel Sciarra
  • Function : Author
Piotr Konieczny
  • Function : Author
Ignacio Faustino
  • Function : Author
Modesto Orozco
  • Function : Author
Ruben Artero
  • Function : Author
Friedrich Metzger
  • Function : Author
Martin Ebeling
  • Function : Author
Harald Schwalbe
  • Function : Author
Leonardo Scapozza
  • Function : Author
  • PersonId : 1046419

Abstract

Modification of SMN2 exon 7 (E7) splicing is a validated therapeutic strategy against spinal muscular atrophy (SMA). However, a target-based approach to identify small-molecule E7 splicing modifiers has not been attempted, which could reveal novel therapies with improved mechanistic insight. Here, we chose as a target the stem-loop RNA structure TSL2, which overlaps with the 5′ splicing site of E7. A small-molecule TSL2-binding compound, homocarbonyltopsentin (PK4C9), was identified that increases E7 splicing to therapeutic levels and rescues downstream molecular alterations in SMA cells. High-resolution NMR combined with molecular modelling revealed that PK4C9 binds to pentaloop conformations of TSL2 and promotes a shift to triloop conformations that display enhanced E7 splicing. Collectively, our study validates TSL2 as a target for small-molecule drug discovery in SMA, identifies a novel mechanism of action for an E7 splicing modifier, and sets a precedent for other splicing-mediated diseases where RNA structure could be similarly targeted.
Fichier principal
Vignette du fichier
s41467-018-04110-1.pdf (2.54 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Loading...

Dates and versions

hal-02115789 , version 1 (30-04-2019)

Identifiers

Cite

Amparo Garcia-Lopez, Francesca Tessaro, Hendrik R A Jonker, Anna Wacker, Christian Richter, et al.. Targeting RNA structure in SMN2 reverses spinal muscular atrophy molecular phenotypes. Nature Communications, 2018, 9 (1), ⟨10.1038/s41467-018-04110-1⟩. ⟨hal-02115789⟩
41 View
93 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More